多组学仪器平台开发商Pleno完成2500万美元B轮融资，支持下一阶段的增长战略

　　Dr. Vik Vaz, CEO at Pleno

　　首席执行官兼Pleno Vik Vaz博士

　　What You Should Know:

　　您应该知道：

　　– Pleno, an innovative multi-omics diagnostics company, announced it has raised $25M in Series B funding and appointed Dr. Vik Vaz as its new Chief Executive Officer (CEO). Key investors Deerfield Management, Foresite Capital and Medical Excellence Capital remain committed to supporting the next phase of the company’s growth strategy..

　　–创新的多组学诊断公司Pleno宣布，已在B轮融资中筹集2500万美元，并任命Vik Vaz博士为其新任首席执行官（CEO）。主要投资者Deerfield Management、Foresite Capital和Medical Excellence Capital仍致力于支持公司下一阶段的增长战略。。

　　– Dr. Vaz, a seasoned leader with extensive experience in the life sciences and medical technology sectors, will guide Pleno’s expansion as the company scales its commercial operations.

　　–Vaz博士是一位经验丰富的领导者，在生命科学和医疗技术领域拥有丰富的经验，随着公司规模的扩大，他将指导Pleno的扩张。

　　Dr. Vaz Bio/Background

　　Vaz博士简介/背景

　　Dr. Vaz an actively licensed physician with training and experience from prestigious institutions like Harvard Medical School and the University of Miami. Dr. Vaz served most recently as head of strategy and market intelligence and a leader of the companion diagnostics business at Illumina. Prior to that, he has served as a partner at Boston Consulting Group and McKinsey and Company, advising leading pharmaceutical and medical device companies.

　　Vaz博士是一名积极执业的医生，受过哈佛医学院和迈阿密大学等著名机构的培训，拥有丰富的经验。Vaz博士最近担任Illumina的战略和市场情报主管以及伴随诊断业务的领导者。在此之前，他曾担任波士顿咨询集团（Boston Consulting Group）和麦肯锡公司（McKinsey and Company）的合伙人，为领先的制药和医疗器械公司提供咨询服务。

　　His leadership and expertise will be instrumental in driving the company’s growth, expanding its reach, and bringing its innovative technology to a wider audience..

　　。。

　　“I am excited to be joining Pleno and look forward to leading this exceptional team,” said Dr. Vaz. “We are poised to bring a transformational new technology to market that will improve patient care and drive advances in biological understanding. The data we have generated already will spur impact across oncology, infectious disease and many other clinical applications.”.

　　瓦兹博士说：“我很高兴能加入普莱诺，并期待着领导这支出色的团队。”。“我们准备将一种变革性的新技术推向市场，这将改善患者护理并推动生物学理解的进步。我们已经产生的数据将刺激肿瘤学，传染病和许多其他临床应用的影响。”。

　　Pleno is developing the RAPTORTM multi-omic instrument platform, a groundbreaking technology that aims to revolutionize biological target detection. This platform:

　　Pleno正在开发RAPTORTM多组学仪器平台，这是一项开创性的技术，旨在彻底改变生物目标检测。此平台：

　　Simplifies multi-omics: Makes complex multi-omic analysis more accessible and affordable.Enhances performance: Delivers unprecedented improvements in accuracy and efficiency.Reduces costs: Offers a cost-effective solution for life science research and diagnostics.Increases scalability: Enables broader adoption of multi-omics across various applications..

　　简化多组学：使复杂的多组学分析更容易获得和负担得起。提高性能：在准确性和效率方面实现前所未有的改进。降低成本：为生命科学研究和诊断提供具有成本效益的解决方案。提高了可扩展性：能够在各种应用程序中更广泛地采用多组学。。